NMNAT3

Across TCGA pan-cancer cohorts, NMNAT3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NMNAT3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NMNAT3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NMNAT3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where NMNAT3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.560	0.258	<.001	61	view →
CCRCC	DFS	Quartile	II,III,IV	0.439	0.923	.003	17	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	15	view →
LUAD	OS	Quartile	II,III,IV	0.738	0.305	.005	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NMNAT3–PDAC (OS)

Open the PDAC breakdown →